Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in Albania has been increasing steadily over the years, driven by various factors such as an aging population, rising cancer cases, and an increase in healthcare spending.
Customer preferences: Albanian customers prefer oncology drugs that are effective and affordable. They are highly influenced by recommendations from their healthcare providers and tend to opt for drugs that have been approved by the European Medicines Agency (EMA).
Trends in the market: There has been a growing trend towards the use of targeted therapies in Albania. These drugs are designed to target specific cancer cells and are often associated with fewer side effects compared to traditional chemotherapy. Additionally, there has been an increase in the use of immunotherapy drugs, which work by stimulating the body's immune system to fight cancer cells. The introduction of biosimilars has also led to increased competition in the market, resulting in lower prices for oncology drugs.
Local special circumstances: The Albanian healthcare system is largely publicly funded, with a small portion of the population opting for private healthcare. The government has been investing in improving the healthcare infrastructure and increasing access to oncology drugs. However, there are still challenges in terms of access to healthcare services, particularly in rural areas. Additionally, there is a lack of specialized oncologists in the country, which has led to delays in diagnosis and treatment.
Underlying macroeconomic factors: Albania has been experiencing steady economic growth over the years, which has led to an increase in healthcare spending. The government has been investing in improving healthcare infrastructure and increasing access to healthcare services. However, the country still faces challenges such as high unemployment rates and a large informal economy, which may impact the affordability of oncology drugs for some segments of the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
